This result was consistent with the recent result from clinical trial PROFILE‐1014 19, and multivariate analysis showed positive results, which suggested that the usage of crizotinib in the management of ALK‐positive NSCLC brain metastasis. The gene discussed is ALK; the disease is non-small cell lung carcinoma.